Darden James Matthew 4

What Happened

• James M. Darden, Co‑Chairman, CEO and Director of Globe Life (GL), both sold and received shares in transactions reported Feb 25–27, 2026. He disposed of a total of 19,168 shares (9,641 shares to cover exercise/tax obligations and 9,527 shares sold in the open market) for combined proceeds of about $2,764,860. At the same time he was credited with 77,290 shares via awards/derivative grants (recorded at $0), including a 48,200-share derivative grant subject to future exercisability/vesting.

Key Details

• Dates & amounts:
  • 2026-02-25: Acquired 24,499 shares (award) at $0.00.
  • 2026-02-25: Disposed 9,641 shares @ $144.15 to satisfy exercise price / tax liability (F).
  • 2026-02-27: Sold 6,471 shares @ $144.14 (open market) — $932,718.
  • 2026-02-27: Sold 3,056 shares @ $144.76 (open market) — $442,392.
  • 2026-02-27: Acquired 4,591 shares (award) at $0.00.
  • 2026-02-27: Acquired 48,200 derivative shares at $0.00 (see vesting note).
• Sales price range per filing footnotes: approximately $143.56–$145.15 per share; reporting person offers to provide exact per-price breakdown on request (F1).
• Vesting/exercise note: the 48,200-share derivative grant is first exercisable as to 50% on 02‑27‑2028 and the remainder on 02‑27‑2029 (F4).
• Shares owned after the transactions: not specified in the provided filing details.
• Filing timeliness: reported on 2026-02-27 for transactions on 02-25 and 02-27 (no late filing flag in the filing provided).

Context

• The structure—receiving awards/derivative shares recorded at $0 while selling a portion and using shares to cover exercise/tax obligations—is consistent with option/RSU vesting and routine sell-to-cover activity rather than a straight market purchase. The sale items include tax/price-specified disposals (code F) and open-market sales (code S). The derivative award with a 2028–2029 exercisability schedule indicates future vesting/exercise windows rather than immediate free stock.